Erythropoietin for Infants With Brain Injuries Due to Oxygen Deprivation at Birth

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Erythropoietin (Epo) is a hormone normally found in the body that may protect brain cells from damage due to lack of oxygen. This study will evaluate the safety of high-dose Epo in infants who did not get enough oxygen during birth.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
• Treatments: Epoetin Alfa

Criteria

Inclusion Criteria

• Infant 6 hours of age or less

• Apgar scores less than or equal to 3 at 1 and 5 minutes

• Weight greater than 2500 grams (5.5 lbs)

• Central venous line in place

Exclusion Criteria

• infants are ineligible if they do not meet the inclusion criteria above